Pharmaceutical Technology

JULY 15, 2025

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.

40

40

PharmaShots

FEBRUARY 22, 2023

A qualifying medication is prescribed by their healthcare provider The patients who have no insurance or have Medicare Part D Patients who are not enrolled in Medicaid, full Low-Income Subsidy, or Veterans (VA) benefits. The patient must-have commercial health insurance to use the savings card. Virgin Islands.

Insurance 64

Insurance Compounding Dosage Communication 64

Pharmaceutical Technology

JUNE 25, 2025

According to GlobalData’s catalyst calendar, Moderna’s mRNA-1647, an mRNA vaccine, is expected to receive US approval in 2026 for cytomegalovirus infections. Malone, an early mRNA pioneer, has made unfounded claims regarding the dangers of mRNA vaccines, which have sparked significant public backlash.

Vaccines 52

Vaccines Packaging Hospitals Communication 52

Pharmaceutical Technology

JULY 15, 2025

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.

52

52

Pharmaceutical Technology

JULY 15, 2025

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.

52

52

Pharmaceutical Technology

JULY 7, 2025

KalVista will receive an upfront payment of $11m, with an additional $11m contingent upon achieving a regulatory milestone anticipated by early 2026. In April 2025, KalVista Pharmaceuticals granted Kaken Pharmaceutical the commercialisation rights for sebetralstat in Japan. Sign up for our daily news round-up!

FDA 122

FDA Packaging Communication Hospitals 122

Pharmaceutical Technology

JULY 14, 2025

While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit.” We may still continue to send you service-related and other non-promotional communications. We believe the CMC observations are readily addressable, and many have already been addressed.

Communication 52

Communication Packaging Hospitals FDA 52

Pharmaceutical Technology

JULY 14, 2025

A target action date of 28 April 2026 has been set under the Prescription Drug User Fee Act (PDUFA). The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat adults with virologically suppressed human immunodeficiency virus (HIV)-1.

FDA 52

FDA Packaging Research Laboratories Hospitals 52

Pharmaceutical Technology

JULY 9, 2025

The financial impact of this agreement on JCR’s consolidated results for the fiscal year ending 31 March 2026 has already been included in the current earnings forecast. We may still continue to send you service-related and other non-promotional communications. Sign up for our daily news round-up!

Packaging 52

Packaging Communication Hospitals Insurance 52

Pharmaceutical Technology

JUNE 11, 2025

June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The company intends to introduce its inaugural product candidate into clinical trials by 2026. The company is progressing several programmes, intending to introduce its inaugural product candidate into clinical trials by 2026.

Communication 52

Communication Hospitals Packaging Insurance 52

Pharmaceutical Technology

JULY 1, 2025

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.

FDA 52

FDA Packaging Communication Hospitals 52

Pharmaceutical Technology

JULY 14, 2025

A decision by the FDA is expected in H1 2026. Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications.

Labelling 52

Labelling Vaccines FDA Packaging 52

Pharmaceutical Technology

JUNE 26, 2025

The group had set a fundraising target of $11.9bn for its 2026-2030 budget. Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications.

Vaccines 59

Vaccines Packaging Communication Hospitals 59

Pharmaceutical Technology

JUNE 16, 2025

However, Blincyto’s loss of exclusivity in Europe (2025) and the US (2026) is expected to significantly reduce its future sales. According to GlobalData’s analyst consensus forecast, surovatamig’s global sales are projected to reach $138 million by 2031, compared to $1.7 billion for Blincyto. Sign up for our daily news round-up!

Labelling 52

Labelling Communication Vaccines Hospitals 52

Pharmaceutical Technology

JUNE 18, 2025

Experts gathered at the ongoing BIO International Convention in Boston, US, this week were reasonably confident the programme will be reauthorised in a legislative package before its expiry in September 2026. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

FDA 59

FDA Packaging Communication Hospitals 59

Pharmaceutical Technology

JUNE 13, 2025

By GlobalData Learn more about Strategic Intelligence Moderna said it plans to have mRESVIA available for both both younger adults and older adults in the US in time for the 2025-2026 respiratory virus season. This usually begins around November and peaks in the mid-Winter months. Give your business an edge with our leading industry insights.

Vaccines 52

Vaccines FDA Labelling Communication 52

Pharmaceutical Technology

JUNE 10, 2025

As per its IPO prospectus in January, the monotherapy trial was set to commence in Q1 2025, with the combo trial slated for the same quarter in 2026. Two pre-clinical programmes also stood to benefit from cash generated from the IPO. Give your business an edge with our leading industry insights.

Communication 52

Communication Hospitals Packaging Insurance 52

Pharmaceutical Technology

JULY 14, 2025

Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO’s overall budget for 2026-2027 will be lower than that for 2024-2025. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Vaccines 52

Vaccines Packaging Hospitals Communication 52